Announced details
Treatments for pain, autoimmune diseases and neuromuscular diseases, among others (described as drug discovery research areas on which 杏林製薬 is focusing)
A business relationship based on the license agreement. UBE Corporation created the compound, and 杏林製薬 will acquire exclusive worldwide rights to develop, manufacture and market it. 杏林製薬 will pay UBE Corporation an upfront payment, development and sales milestones, and royalties.
Head office: Minato-ku, Tokyo; Representative Director and President: Nishida Yuki (西田祐樹). UBE Corporation creates compounds that serve as seeds for new pharmaceuticals, based on compound design supported by advanced organic synthesis capabilities. Its pharmaceuticals business covers drug discovery research and CDMO operations.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Novel therapeutic drug candidate compound (compound name not disclosed) |
| Counterparty | UBE Corporation |
| Counterparty overview | Head office: Minato-ku, Tokyo; Representative Director and President: Nishida Yuki (西田祐樹). UBE Corporation creates compounds that serve as seeds for new pharmaceuticals, based on compound design supported by advanced organic synthesis capabilities. Its pharmaceuticals business covers drug discovery research and CDMO operations. |
| Relationship with the Company | A business relationship based on the license agreement. UBE Corporation created the compound, and 杏林製薬 will acquire exclusive worldwide rights to develop, manufacture and market it. 杏林製薬 will pay UBE Corporation an upfront payment, development and sales milestones, and royalties. |
| Contract Date | 23 March 2026 (announced as the agreement execution date) |
| Applicable area | Treatments for pain, autoimmune diseases and neuromuscular diseases, among others (described as drug discovery research areas on which 杏林製薬 is focusing) |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The parties aim to combine the compound created by UBE Corporation with 杏林製薬's research and development expertise to deliver new treatment options at an early stage to patients for whom existing drugs do not provide sufficient efficacy.